We studied 23 patient s (from JJ [am ilies] who had Waardenburg's syndrome. Pati ents were evaluated by conventional audiometric methods and by distortionproduct otoacoustic emissions to determin e the penetranc e and the degree and type ofhearing loss. Twelve of the patients had the type I form of the syndrome and JI had type II. Overa ll, wefound hearin g loss in J9 ofthe 23 patients (83 %); hearing loss affected nin e type I patients (75 %) and 10 type II patients (9J %). Five type I patients (42 %) and eight type II patients (73 %) had a hearing loss of> 100 dB. Bilateral symmetrical hearing loss was the most common type ofloss, as it was seen in six ofthe type I patients (50 %) and eight of the type II patients (73 %).
Introduction
Waardenburg's syndrome was first described in 1951 as a new entity characterized by congenital sensorineural hearing loss and pigmentary disturbances of the skin, hair, and eyes (figure).' Waardenburg' s syndrome is clas sified as one of two types, according to the presence (type I) or absence (type II) of dystopia canthorum.' The penetrance of congenital hearing loss, the mo st significant clinical finding in patients with this syndrome, has been reported From to be 35 to 70% in type I patients and 55 to 85% in type II patients.l? W hen it occurs, the hearing loss can be eit her corn ple te or partial and bilateral or uni latera l, The incidenee of unilateral loss has been reported to be 4 to 13%. [3] [4] [5] As is the case with other syndromic hearing losses, a significant number of patients with Waardenburg's syndrome have both low-and high-frequency hearing losses and impairments, as indicated by U-shaped audiograms.Y The dick auditory brainstem response (ABR) is highly sensitive in detecting childhood hearing loss, but its primary drawback is its lack of frequency specificity.
Distortion-product otoacoustic emissions (DPOAEs), firstdescribed by Kemp in 1979 , are the acoustic energies in the external ear canal that emanate as aresult of the simultaneous stimulation of the cochlea by two con tinuous pure tones, which are referred to as primaries. ' The freque ncy of this acoustic energy is closely related to the freq uency of two primary stimuli: fl and f2 . As non linear responses tha t are present in almost all nor rnal ears and that have high-frequ ency specificity, DP OAE s are useful in the diag nosis of hearing loss, especially in children .v?
Our search of the literature found on lyone previous stud y that invest igated the u se of D POAEs in Waardenburg' s syndrorne. ' ? In this artic le, we describe our study ofWaardenburg' s syndrome in 23 patients from 11 families , We discuss its penetrance and the degree and type of he aring loss as determined by conventional methods and by DPOAEs in patients with both type I and type II syndrome.
M aterials and methods
Twenty-three patients (fro m II fami lies) with Wa ardenburg's syndrome were followed at the University of Istanbul ' s Center for Deaf Children between 1990 and 1997. The 13 females and 10 male s ranged in age from 2 to 40 yea rs (mean: 17).
Twelve of these patients met the diagnostic criter ia for type I Waardenburg's syndrome as proposed by Farrer et al," and II were diag nosed with type II syndro me, as ENT Severeand sometimes fatal events, some due to hypersensitivity, and some of uncertain etiology, havebeen reportedin patients receiving therapy with all antibiotics. These events may be severe and generally occu r following the administration of multiple doses. Clinical manifestations may include one or mare of the following: rash , fever, eosi nophilia, jaundice, and hepatic necrosi s. Pseudom embranous eoti tis has been reportedwithnearl y all antibaeterial agents andmay range in severity from mild to life-threatening , Therefore, it is import ant to eonsiderthis diagn osis in patients who presentwith diarrhea subsequenttothe administration of antibaeterial agents. Treatment withantibacterial agents al lersthe normal floraof thecolon and maypermit overgrowthof clost ridia. Studiesindicate thatatoxin produced byClostridium difficife is one primary cause of "antibiotic-associaledeolitis." Allerthediagnosis 01 pseudomemb ranous eolit ishas beenestablished, therapeutie measuresshouldbeinitiated. Mild cases of pseudomembranous coli tisusually respand todrugdiscontinualionalone. In moderaIe to severe cases, consideratian should begiven to management withfluids and eleetrolytes, prolein supplementation, and treatment wilh an anlibaeterial drug el inieally eHeelive against C. dittieile eolitis.
Although not observed in moxilloxaein el inieal trial s, Aehilles and olher tendon rupt uresthat required surgieal repair or resulted in prolanged disability have been reported with quinolones. Moxilloxaein should bediseontinued il the patient experiences pain,inflammation, or rupture of atendon. • that moxitloxaein should beavoided in patients reeeivingClass lA (e.g. quinidine, procainamide) or Clas, III (e.g. amiodarone, sotalol) ant iarrhythmieagents. • that moxilloxaein may add to theOTe prolongi ng eHeets 01 otherdrugs such aseisapride , erylhromyein, antipsychotics, and tricyclic ant idepressants. • to informtheir physici an ofany personal orfamily history ofOTc prolongation orproarrhythm iceondilionssuch as reeent hypokalemia, signilicant bradyeardia,aeutemyoeardial isehemia. • to informtheir physicianof anyolhermedications when taken concurrently with moxifloxacin. including oveHhecounler medications. No clinically significant drug-drug interactions between Iheophylline, warlarin, digoxin, Dr glyburide have been : : : ' i ; 0~~e~~: hor~~~~Ĩ~; i n T~ §~~h t~:~i t~~~X~~t~Of~8i~~;)d ranilidine have been shown notto alter the phar-Warfarin: Nosignificant ettect of moxifloxacin on R· and S· wartari n was detecled in a eli nical study involving24 healthy volunteers. Nosigni ficantchanges in prothrombintimewere noledin thepressneeof moxifloxacin. However. smce some quinolones have been reported to enhance the anticoagulant eneets of warfar in or its derivaüves in the patient population, the proth rombin timeor other sui table eoagulationtest shouldbeelosely monitared il aquinolane antrnicroblal is administered concom itantlywith wartarin oritsderivatives.
Orugs metabolized byCytoehromeP450 enzymes: In vüro studies with cytochrorne P450isoenzymes (CYP)indicat e that moxifloxaein does notinhibil CYP3A4, CYP206, CYP2C9, CYP2C19, or CYP1A2 , suggesting thatmoxi floxaein is unlikel y toalter the pharmaeokineties of drugsmetabolized by these enzymes (e.g. midazolam, eyelosporine, wartarin, theophylline). Nonsteroidal anti-inflammatory drugs(NSAIDs): Although notobserved with moxilloxaein inpreelini cal andei inical trials, theconcomnamadminist ration of a nonsteroidal anü-lnüarnmatorydrugwitha quinolonemay increasethensks of CNS stimulationand convuislons,(See WARNINGS.) Carcinog enesis, Mutagenesis, Impairmental Fertility: Long termstudiesin animals to determinethecarcinoqenic potential of moxifloxacin have not been pertormed. Moxilloxaeinwas notmutageniein4 bacterial strains(TA98,TA100, TA1535, TA1537) usedintheAmes Salmonella reversion assay. Aswithotherquino lones, the positiva response observed with moxifloxacin in strai n TA 102 using thesarne assay may bedue totheinhibitionofONAgyrase.Moxifloxaein was not mutagenie intheCHOIHGPRTrnarnmaliancell gene mutationassay. Anequivocal resultwas abtained in thesame assay when '179 eelis were used. Moxifloxacin was elastogenic in the'179 chromosome aberration assay, but it did notinduce unscheduled DNA synthesisin cult ured rathepatocyt es. Therewasno evidanee of genotoxicityin vivo in amicronucleus testor adominant lethal test in miee. Moxilloxaein had no etteet onfertilityin maleandfemale rats atoral doses ashighas500 mglkg/day, approximately 12 1imes the maximumreeommended human dose based on body surrace area (mgl m'). At 500 mglkg ther e were slight eneets onspe rmmorphology (head-tall separatian) in male rats and ontheestrouseyelein temalerats. Pregnancy: TeratogenieEff eels, Pregnaney Category C: Moxifloxacin was notteralogenic when administered to pregnantrats duringorganogenesis at oral doses ashighas 500 mglkglday or 0.24 times the maximum reeommendedhuman dose based on systemie exposure(AUC), but deereasedfetal body weightsand slightly delayed letal skeletal development (indicativeofletotoxieity) wereobserved. Intravenous adrninisfratonof 20 mglkglday (approximateiy equal to the maximum reeommended human oral dose basedupon systemieexposure)fo pregnant rabbits duringorganogenesis result edin deereased letal body weights and del ayed fetalskeletal ossification. When rib andvertebral mal format ions werecombined, therewas anincreased fetal and litter inci denee ofthese etteets. Signs01maternai toxi eity in rabbitsal thi s doseinel uded mortality,abortlons, markedreduetionat food eonsumplion, deereased water int ake, body weight loss and hypoaetivity.Therewas no evidenee of leratogenieity wnen pregnant Cynomolgusmonkeys weregiven oral doses ashigh as100 mglkg/day (2.5 times themaximum recommended human dose based upon systemic exposure). Anincreased incidence of smaller letuses was observed at 100 mglkglday. In anoral pre-andpostnatal development studyeondueted in rats, eHeets observed at 500 mglkgl dayineluded slight increases in dur ation of pregnaneyand prenalalloss, redueedpup birt h weight and deereased neonatal survival. Treatment-related matemal monality oeeurred during gestation at 500 mglkg/day in thisstudy.
Since thereare noadeq uateor well-controHed studies in pregnant women, moxifloxacin should beusedduring pregnaneyonly il thepotential benelit juslifies thepotential riskfo thefetus. Nursing Mot hers: Moxifloxaci n is excreted inthebreast mil kof rats. Moxifloxacinmay alsobeexcretedin human mi lk. Becauseof thepotential for serious adverse reactions in infantsnur singfrom motherstaking moxilloxacin,a decision should bemadewhethe r to discontinue nursing orto discontinue the drug, takinginto account theimportance of the drugto themother.
PedlatrieUse: Sa letyand eHeeliveness inped iat riepatients and adoleseents less than18 years01age have not been established. Moxilloxaein eauses art hropathy in juvenileanimals. (See WARNINGS.) Geriatri c Use: Incontrolled multiple-dose cli nical trials, 23%of patients receiving moxifloxacin weregrealer than or equal to 65years ofageand 9%Vleregreater than orequal to 75years 01age. Theelinical trial data demonstratethat there is nodifferenee in thesafety and eHieaey 01moxilloxaein In patients aged 65 or older eompared to younger adul ts. ADVERSE REACTIONS Clinica! eHicaey trials enrolled over 4900moxifloxaein treated pat ients,of whom ove r 4300 palients reeeived the400 mg dose. Most adverse events reported in moxifloxacin trials were described as mil d to moderate in severity and required notreatment. Moxifloxacin was discontinued duetoadve rsereactions thought to bedrug-related in 3.8% of patients. Adverse reaetions, judged by investigators to beatleast possibly drug-related, oeeurringin greaterthan or equal to 1% 01 moxilloxaein treatedpatient s Viere: nausea (8%),diar rhea (6%), dizziness (3%), headaehe (2%), abdominal pain (2%), vomiting (2%),tasteperversion (1%), abnormal liverfunetion test(1%),and dyspepsia (1%). Additional events, judgedbyinvestigators tobeatleast possiblydrug-related, that oeeurred in greater than 0.05%and less than 1% of moxifloxaeintreatedpatientswere: Liu et al." We also evaluated pigmentary disturb ances accor ding to the criteria described by the latter author.
All patients were examined otoscopically, and all were eva luated by tympanometry, DPO AEs, and either puretone audio metry OI' ABR. In 12 of the patients, airconduction thresholds were determined at 500 Hz and I, 2,4,6, and 8 kHz by pure-tone audiometry. The degree of hearing loss was determin ed by examining the mean values across the frequ ency range. The II patient s who could not be subjected to pure-tone audiometry becau se of their age had their hearing thresholds determined by click ABR . Hearin g threshold results were placed into one of four categories (::;30, 31 to 60, 61 to 100, and> IOO dB HL). In cases of bilateral asy mmetrical hearing loss, the classific ation was based on the better ear.
A Cele sta 503 Otoac oustic Emi ssion Analyzer (Madsen Electronic s;Taastrup, Denmark) was used to test DPOAEs. DPOAEs were determ ined at frequencies of 500 and 750 Hz and at I, 1.5, 2, 3, 4,6, and 8 kHz to obtain a "DPgram." The ratio of the two prim aries (f2/fl) was 1.22, and their intensity was set at 65 dB sound pressure level. Distortion produ cts were acce pted by the system as valid because the response fell within the range of ±3 standard deviation s of noise and <80 dB of stimulus level."
Results
All patients were otosco pically normal, and all had type A tympanograms. With' the use of conventional methods and DPOAE, we found that 19 of the 23 patient s (83%) had a sensorineural hearing loss-i-nin e (75%) type I patients and JO (91%) type II patients. No progression of hearing loss was obser ved in any patient during a followup that ranged from 8 month s to 7 years. The incidenee of hearing loss and pigmentary disturb ances are recorded in table I, along with those reported by Liu et al for comp arison purposes." In both type I and II patients, the most common degree of hearing loss category was > IOO dB HL. Profound hearin g loss was detected in five type I patients (42%) and eight type II patients (73%); according to X 2 analysi s, the difference between the two group s was statistically significant (p<O.O I). There were no statistically significant differences with respeet to the penetrance ofhearing loss in the other ranges of hearing thresholds (table 2) .
The most comm on type of hearing loss was bilateral hearing loss, which was seen in 18 of the 23 patients (78%) ( table 3) . Bilateral symmetrical hearing loss was more common than unilateral and bilateral asymmetrical hearing loss in both types of the syndrome. Onlyone patient (type II) had unilateral hearing loss. Moreover, bilateral symmetrical hearing loss was more common in type II patients than in type I patients.
DPOAEs were normal in the four patients (three type I and one type II) who had normal hearing as determined by conventional audiometry. In these patients, emission amplitudes were above the noise floor at all frequencies between 500 Hz and 8 kHz, and these responses were accepted by the system as valid. No patient had a notch in the DP-gram.
In 11 of the 16 patients whose hearing thresholds were 60 dB HL or worse, thresholds were determined by click ABR. In five of these 11 patients, results in seven ears were incompatible with DP-gram findings . In five of these seven ears , DPOAE amplitudes were significantly above the noise floor at 500 Hz, 750 Hz, and I kHz and below the noise floor at the higher frequencies. In the other two ears , emission amplitudes were above the noise floor only at 500 and 750 Hz.
Discussion
Audiologic tests of the 23 patients showed that the penetrance of sensorineural hearing loss was 83%. Penetrance was 75% in the type I group and 91% in the type II group . In a study by Hageman and Delleman, the penetrance of hearing loss was 36 and 57% in type I and type II patients, respect ively!'; these rates are remarkably lower than those in our study. However, in two more reeent studies, Newton " and Liu et al" reported penetrance rates of 69 and 58%, respectively, in type I patients and 87 and 78% in type II patients; these findings are more in line with our own. One common finding among all four studies was that the penetrance of hearing loss in type II patients was remarkably higher than in type I patients. 706 In our study , the most common category of degree of hearin g loss in both types of patients was >100 dB HL-42% in type I patients and 73% in type II patients; the difference between the two groups was statistically significant (p<0.01). Newton reported hearing losses of >1OO dB HL in 34% of type I patients and 36% of type II patients .' Liu et al observed this degree of hearing loss in 58% of type I patients and 47% of type II patients (table  2) .12It is interesting, however, that while the penetrance and degree ofhearing loss is greater in type II patients, the expression of pigmentary disturbances on the skin and abnormalities of the facial skeleton are more common in type I patients (table 1) . Type II patients are more likely to be identified by their families arid primary care physicians by severe hearing loss than by skeletal abnormalities or pigmentary disturbances. Many type II patients who do not have hearing loss, especially those in developing countries, are considered by their families to be normal, and therefore they do not seek medical attention . On the other hand , because of obvious phenotypic charaeteristics such as dystopia canthorum, type I patients are easily recognized when no hearing loss is present.
In our study, bilateral symmetrical sensorineural hear- (table 3) . In a study published in 1977, Hageman reported bilateral symmetrieal hearing loss in about 25% of type I patients and in almost 50 % of type II patients .' These percentages are lower than those reported by Newton" and those of our study. However, our findings are in agreement with those of Hageman with respeet to the fact that the penetrance of bilateral symmetrical hearing loss was greater in type II patients than in type I patients. By contrast, Newton" and Liu et al" both reported an equal distribution of bilateral symmetrical hearing loss in the two types of patients. As mentioned earlier, the higher penetrance in our study can probably be attributed to the fact that the diagnosis was made by identification of hearing loss rather than by phenotype. Newton's data on 79 patients, who belonged to 10 families with Waardenburg's syndrome, were not affected by the reasons that these patients had visited their physician. DPOAEs are ideal for predicting hearing loss and puretone audiogram shape because they are (I) present in all ears with normal hearing, (2) absent in ears with a hearing threshold <50 dB HL, and (3) frequency-specific. 8 • 9 •'s In a small study published jointly, Liu and Newton reported the detection of a notch between 1,000 and 3,000 Hz in the DP-grams of seven of eight (88%) normalhearing patients with Waardenburg's syndrorne. '? The notch was present in all five oftheir type II patients and in two of their three type I patients. They speculated that the notch was the result of either a subelinical pathologic change or some other physical phenomenon. We found no such notch in our study, and there are no other reports in the literature of DPOAE findings in patients with Waardenburg's syndrome. If we combine the four patients in our study who had normal hearing with Liu and Newton's eight patients, we can extrapolate that somewhat more than half (7 of 12 in these two studies) of patients with Waardenburg' s syndrome who have normal hearing can be expected to have subelinical pathologic changes.
In Waardenburg' s syndrome, as in other hearing losses of genetic origin, patients can experience low-and highfrequency hearing losses and exhibit U-shaped audiographic results.v" Newton found either unilateral or bilateral residual low-frequency (Fisch type I) losses in audiographic shapes in 29 of 60 patients with Waardenburg's syndrorne.':" Liu reported that the penetrance oflow-frequency hearing loss in Waardenburg's syndrome was 14%.17 It is not usually possible to determine these types ofhearing losses by elick ABR, which is not frequency-specific . In five patients (seven ears) in our study whose hearing thresholds were 60 dB HL or worse by elick ABR, DP-grams showed that emission amplitudes were significantly above the noise floor at 500 Hz, y 750 Hz, and 1 kHz in five ears . When one considers that emissions are absent in ears that have a hearing threshold of 50 dB HL or worse, one can speculate that hearin g might be better than expected, perhaps even normal, at these low frequencies."
We conelude that patients whose hearing threshold s are determ ined by elick ABR testing should undergo DPOAE testing to estimate low-frequen cy hearing. The routine use of DPOAEs in children with Waardenburg's syndrome can deteet high-frequency hearing loss, and thus it can prevent overamplification in the lower frequencies during the fitting of a hearing aid, which is the primary therapy for patient s with this syndrome.
